Found vs Omzo: Personalized biology-first care vs clinician-guided compounded plans
Quick verdict: Found vs Omzo
Found and Omzo both connect patients to GLP-1 treatment options, but their approaches differ: Found emphasizes a biology-first, personalized weight loss program with insurance handling and plans starting as low as $39, while Omzo is a clinician-guided platform focused on personalized compounded semaglutide with prices starting at $179. Early verdict: choose Found for insurance support and a broader biology-based program; choose Omzo if you want clinician-reviewed compounded semaglutide or prescriptions for branded drugs subject to pharmacy fulfillment.
Explore Found plans starting as low as $39
How they compare at a glance
| Criteria | Found | Omzo |
|---|---|---|
| Approach | Biology-first personalized medically supervised program | Clinician-guided plans reviewed by licensed U.S. providers |
| Starting price | Get started for as low as $39 | Semaglutide starting at $179 |
| Medication options | Semaglutide, tirzepatide, compounded and branded access via insurance | Compounded semaglutide and tirzepatide; prescriptions for branded meds filled separately |
| Insurance | Most insurance now accepted; Found handles insurance paperwork | Users are responsible for pharmacy and costs for branded meds; Omzo pays pharmacies for compounded meds |
| Regulatory note | Compounded GLP-1s are not FDA-approved | Compounded drugs are not FDA-approved |
1. Program design and clinical emphasis
Found promotes a biology-first personalized medically supervised program that evaluates metabolic biology, hormones, sleep, and behavior to tailor weight loss. Omzo emphasizes clinician-guided GLP-1 care where licensed U.S. providers review plans and determine eligibility. The distinction is direct: Found positions weight loss around a broader biology-based plan, while Omzo centers on clinician review for medication eligibility and prescribing decisions.
See Found’s biology-first program details
2. Price and payment handling
Found advertises getting started for as low as $39 and notes affordable monthly plans plus insurance handling for many users. Omzo lists semaglutide starting at $179 and tirzepatide at $279. Found explicitly states it handles insurance paperwork and accepts most insurance, while Omzo notes that if a branded medication is prescribed, the patient is responsible for filling it and paying associated costs. Preserved qualifiers apply: advertised pricing for branded GLP-1s may require commitments and coverage varies.
3. Medication sourcing and regulatory notes
Both providers offer access to compounded GLP-1 options and both include regulatory notes that compounded medications are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or quality. Found highlights compounded semaglutide and tirzepatide and also mentions brand-name options through insurance and programs for Medicare Part D members. Omzo describes a primary compounded medication program produced by state-licensed or FDA-registered facilities and clarifies that Omzo does not sell or ship branded medications directly.
4. Insurance, pharmacy, and logistics
Found emphasizes insurance acceptance for many users and says it handles insurance paperwork, including references to a Medicare GLP-1 Bridge Program that may help eligible Part D members access brand-name GLP-1s for as little as $50 per month under specific terms. Omzo notes that providers write prescriptions based on clinical judgment and that if branded meds are prescribed the patient must fill them and cover costs. Omzo also states medication costs for compounded drugs are included in fees it collects and Omzo pays the pharmacies that fulfill those orders.
Explore Omzo clinician-guided plans starting at $179
5. Who should check eligibility and expectations
Found is described as best for people who want weight loss built around their biology and highlights personalized medically supervised care. Omzo is described as best for people who confirm eligibility, medication, total cost, renewal terms and state availability before enrollment. Both note that individual results vary and that eligibility is determined by provider review or clinician judgment.
Conclusion: Found vs Omzo
In a direct comparison, Found focuses on a biology-first, personalized program with lower advertised entry pricing and active insurance handling, while Omzo offers clinician-guided access to compounded semaglutide with higher starting fees and clarity that branded prescriptions are filled by the patient at their chosen pharmacy. Both state that compounded medications are not FDA-approved and both leave final prescribing decisions to clinicians. Use the Found vs Omzo distinction above to decide based on insurance needs, program design, and preferred medication sourcing.
Compare Omzo medication options and shipping
Choose Found if…
You want a biology-first, medically supervised weight loss program that handles insurance paperwork for many patients and offers plans advertised starting as low as $39 with options for compounded and branded GLP-1 access through insurance.
Choose Omzo if…
You prefer clinician-guided compounded semaglutide or tirzepatide plans reviewed by licensed U.S. providers and are prepared to manage pharmacy fulfillment and costs for any branded prescriptions. Both providers note that compounded drugs are not FDA-approved and prescribing is subject to clinician review and eligibility.